Cullinan (CGEM) Q2 R&D Jumps 68%

Cullinan Therapeutics (NASDAQ:CGEM), a clinical-stage biopharmaceutical company focused on developing therapies for cancer and autoimmune diseases, released its second quarter 2025 earnings on August 7, 2025. The period was marked by higher spending as it advanced its clinical trials and expanded the pipeline, particularly with the new velinotamig autoimmune candidate. Cullinan reported a net loss of $70.1 million, or ($1.07) per share (GAAP).—$0.24 higher than the estimated loss per share of ($0.83). No revenue was reported. Overall, the quarter showed heavy investment in research, increased operating expenses, and a continued pipeline focus, but also highlighted growing losses as Cullinan awaits future clinical and regulatory milestones. Source: Analyst estimates for the quarter provided by FactSet. Cullinan Therapeutics develops new treatments for immune-system disorders and cancer. It operates as a clinical-stage company, which means its products are not yet approved for sale and generate no commercial revenue.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool